Autobio Diagnostics is set to exit the molecular diagnostic test provider through a purchase by women’s health-focused technology provider Hologic.
Women-focused medical technology producer Hologic has agreed to acquire Mobidiag, a Finland-headquartered molecular diagnostics technology developer backed by clinical diagnostics product maker Autobio Diagnostics, for €668m ($795m).
The deal, which is expected to close in the fourth quarter of the 2021 fiscal year, involves a cash payment of $714m combined with $81m of net debt financing.
Founded in 2000, Mobidiag produces polymerase chain reaction-based tests and equipment for acute care conditions including gastrointestinal and respiratory infections.
The company’s offering includes…
